Sun Pharma plans to leverage its global presence to accelerate patient access to this crucial treatment
Capital expenditure in the CV industry is also expected to rise significantly to Rs 58-60 billion in FY25 and FY26, up from Rs 34 billion in FY24
Typhoid and shigellosis remain serious public health threats, particularly in low-resource settings
He highlighted that the company is committed to increasing investments in EVs and advanced technology with a customer-centric approach
The future of sustainable mobility will involve multiple technologies, says commercial vehicles operator
Enfield, TVS see growth while Bajaj, Hero struggle
This initiative addresses long-standing concerns over inconsistent certificate formats and verification challenges across India's 28 states
India has also surpassed the US in the number of FDA-registered generic manufacturing sites
Previously, companies exporting drugs from India had to apply for a customer- and quantity-specific NOC each time they received an order
In 2014, the share of OAI status globally stood at 6 per cent which has now more than doubled standing at 14 per cent
Megafine currently operates two USFDA-approved manufacturing facilities located in Nashik, Maharashtra, and Vapi, Gujarat, and specialises in niche, high-margin APIs, primarily used in chronic disease
This surge is also being driven by India's cost advantages compared to Western countries, 90 per cent faster project startup times, and global supply chain realignments
The facility, which occupies approximately 524,000 square feet across two towers in HITEC City, will focus on harnessing AI, data science, and digital innovation to accelerate research and development
Shingles, caused by the reactivation of the varicella-zoster virus-the same virus responsible for chickenpox-is a painful disease that can lead to severe and long-lasting complications
Company's expansion move is linked to its decision to acquire Camso, a global leader in OHT solutions
A key component of the transactions includes a $650 million funding arrangement for its U.S. subsidiary, Sun Pharmaceutical Industries Inc. (SPI Inc.), to support business expansion
Credit rating agency ICRA forecasts that this growth will be driven by strong export performance, increasing localisation of electric vehicle (EV) components, and rising demand in the aftermarket
This move aligns with the company's aggressive domestic expansion, where it plans to double its centres across India from the current 50 to 100, backed by an investment of Rs 500 crore
In a recent discussion, the company confirmed that while supply chain disruptions previously affected availability, the situation has now stabilised
MaxiVision is also setting its sights on the stock market, with plans to go public within the next two years